CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
基于免疫检查点调控的 CAR-T 细胞疗法治疗血液系统恶性肿瘤
英文原题：CAR-T-Cell Therapy Based on Immune Checkpoint Modulation in the Treatment of Hematologic Malignancies.
查看英文原题
CAR-T-Cell Therapy Based on Immune Checkpoint Modulation in the Treatment of Hematologic Malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法是一种革命性免疫疗法，在治疗某些血液系统恶性肿瘤方面已取得显著成功。然而，该疗法仍存在挑战和局限，并非所有癌症患者都能从单一疗法中获益。因此，基于免疫检查点对CAR-T 细胞疗法进行改造，并将其与免疫检查点抑制剂（ICI）联合，显示出成为治疗血液系统恶性肿瘤更有效策略的潜力。本文概述基于免疫检查点调节的CAR-T 细胞疗法治疗血液系统恶性肿瘤的临床前研究和临床试验进展。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary immunotherapy that has shown significant success in treating certain hematologic malignancies.
However, there are still challenges and limitations associated with this therapy, and not all cancer patients benefit from this therapy alone.
Therefore, modifying CAR-T-cell therapy based on immune checkpoints, and its combination with immune checkpoint inhibitors (ICIs), shows promise as a potentially more effective strategy for treating hematologic malignancies. This article outlines the progress of preclinical and clinical trials of CAR-T-cell therapy based on immune checkpoint modulation in the treatment of hematologic malignancies.
论文信息
- 作者
- Su M、Zhang Z、Jiang P、Wang X、Tong X、Wu G
- 单位
- Department of Hematology, Dongyang Hospital Affiliated to WenZhou Medical University, Dongyang People's Hospital, Dongyang, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Cell transplantation2024 Jan-Dec
- 原文标识
- PubMed 39506457 · DOI 10.1177/09636897241293964
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →